PHARMACY

Former Warner-Lambert CEO receives APhA Foundation’s Jacob W. Miller Award

BY Allison Cerra

WASHINGTON — Joseph Williams, the former CEO of Warner-Lambert, was named the recipient of the American Pharmacists Association Foundation’s 2012 Jacob W. Miller Award, the APhA Foundation said.

The organization said it recognized Williams for his leadership and service to the APhA Foundation capital campaign and advisory committee. Williams also served as APhA honorary president from 2004 to 2005.

In 2009, as part of the APhA Foundation capital campaign, Williams pledged $1 million towards the renovation and enhancement of the APhA library, now named in his honor. These improvements within the library have enabled the APhA library to become the key resource for the profession in promoting pharmacy and innovative practices, such as medication therapy management services, the organization said. What’s more, Williams also instrumental to the donation of the Robert Thom Great Moments in Pharmacy Collection, now housed at the APhA Headquarters Building in Washington, D.C.

APhA Foundation said Williams has continued to maintain his support of the foundation and his leadership was imperative in helping the foundation enhance its mission of optimizing the role of the pharmacist in improving people’s health.

The Jacob W. Miller award was established in 2000 to honor the service of Jacob W. Miller, who served as the APhA Foundation’s president from 1991 to 2000. The award recognizes an individual who has advanced the mission of the APhA Foundation by demonstrating active involvement in the foundation’s programs, exemplary support in establishing and/or maintaining APhA Foundation initiatives or outstanding leadership in carrying out the mission of the APhA Foundation.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Joslin Diabetes Center, American Well to bring telehealth services to patients nationwide

BY Allison Cerra

BOSTON — Joslin Diabetes Center and American Well will collaborate on a telehealth initiative that seeks to improve and expand diabetes patients’ access to high-quality care.

The telehealth services will be powered by American Well’s Online Care technology and will "[apply] a transformative healthcare innovation in support of our mission of improving the lives of people struggling with this disease," Joslin Diabetes Center president and CEO John Brooks said.

"Joslin Diabetes Center is committed to fundamentally changing the landscape of diabetes care today," Brooks said. "Telehealth provides an opportunity to bring together our strengths in research, clinical care, education and awareness in order to create an entirely new class of clinical program — then project care directly to the patients who need it most, at the appropriate time."

"We look forward to joining with Joslin Diabetes Center to help combat a disease that burdens the lives of countless families and, increasingly, our society as a whole," American Well chairman and CEO Ido Schoenberg said. "Joslin is enlisting telehealth in one of its most powerful forms — as a conduit for delivering tailor-made clinical programs to patients who might not otherwise have access to them."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Galen acquires DaunoXome from Gilead

BY Allison Cerra

SOUDERTON, Pa. — A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.

Galen said it has acquired DaunoXome (daunorubicin citrate liposome injection), an anthracycline chemotherapy agent that was first approved in the United States in 1996, and is indicated as a first-line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. Galen said its wholly owned subsidiary, Galen US, will market the drug in the United States. DaunoXome will be made available through wholesalers in the United States.

“We are delighted that we are now able to supply DaunoXome in the United States for the treatment of patients with this devastating disease,” Galen president Mark Scrutton said, “DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS.”


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES